Clinical Trials Logo

Gastroesophageal Reflux Disease (GERD) clinical trials

View clinical trials related to Gastroesophageal Reflux Disease (GERD).

Filter by:

NCT ID: NCT03367195 Active, not recruiting - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Efficacy and Safety of DLBS2411 in the Management of GERD

Start date: November 21, 2017
Phase: Phase 3
Study type: Interventional

This is a 2-arm, prospective, double-blind double-dummy, randomized-controlled study comparing DLBS2411 at a dose of 250 mg twice daily with omeprazole at a dose of 20 mg twice daily, given before morning and evening meals, for an 8-week course of therapy. Subjects should avoid taking meals 2-3 hours before bedtime. The bioactive fraction of DLBS2411 has been proved at cellular and genetic levels to have an antiulcer effect through both suppressing the gastric acidity and enhancing gastric mucosal protection. The anti-secretory effect of DLBS2411 is exerted through the inhibition of H+/K+ ATPase 'pump' as well as down-regulation of the H+/K+ ATPase gene expression, thus suppressing gastric acid secretion; while its cytoprotective defense mechanism works through the promotion of cyclooxygenase-2 (COX-2) derived prostaglandin (PgE2) synthesis, thus promoting gastrointestinal submucosal blood-flow, stimulating secretion of gastric-epithelial mucous and bicarbonate; anti-oxidative activity; and endothelial-nitric oxide (NO) formation. Recent study of DLBS2411 which was conducted in healthy volunteers, demonstrated the effective role and safety of DLBS2411 in suppressing intragastric acidity. Having such mechanisms of action, DLBS2411 is hypothesized to benefit patients with gastric acid disorders such as in gastroesophageal reflux disease (GERD).

NCT ID: NCT02749071 Recruiting - Clinical trials for Gastroesophageal Reflux

An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux

Start date: May 2016
Phase: N/A
Study type: Interventional

The purpose of this investigation is to demonstrate the safety and effectiveness of Lower Esophageal Sphincter (LES) Stimulation System in treating gastroesophageal reflux disease (GERD). This investigation is a multicenter, randomized, double-blind, sham-controlled study. After the implant procedure, subjects will be randomized to either the Treatment Group (immediate stimulation) or Control Group (delayed stimulation) for six months followed by an additional open-label phase in which all subjects will receive electrical stimulation. Subjects continue on stimulation treatment in an extended open-label follow-up phase through 5 years post-stimulation.

NCT ID: NCT02699060 Recruiting - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Plasticity and Its Correlation With Different Forms of Gastroesophageal Reflux Disease

Start date: February 2016
Phase: N/A
Study type: Interventional

This study is proposed to evaluate the role of motoric dysfunctions and burden of different kinds of refluxate on immune cells and the subsequent course of the disease. This study also aims to establish a bridge between instrumental findings (pH-impedance test) and clinical assessments (FSSG questionnaire), aiming to facilitate the use of simple questionnaire techniques in the clinical setting in the future.

NCT ID: NCT02689999 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity

Start date: February 2016
Phase: Phase 4
Study type: Interventional

It is planned to investigate the effect of dexrabeprazole on gastric acid primarily, and then gastroesophageal reflux disease (GERD) symptoms, intraesophageal acidity (reflux) and impedance kinetics.

NCT ID: NCT02555852 Completed - Clinical trials for Community-acquired Pneumonia

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Start date: September 2011
Phase: N/A
Study type: Observational

The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP). The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.

NCT ID: NCT02366169 Recruiting - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Medigus Ultrasonic Surgical Endostapler (MUSE) Registry

Start date: March 2015
Phase: N/A
Study type: Observational [Patient Registry]

This registry is intended as an observational, post-marketing surveillance tool. The registry allows collection of baseline demographics and user experience of the commercially available MUSE system. Data collection aims to aggregate a minimum of 3 years follow-up on a large number of subjects during use outside the constraints of a prescribed clinical study.

NCT ID: NCT02320981 Completed - Clinical trials for Functional Dyspepsia

Mucosal Impedance in Pediatric Population

Start date: August 2014
Phase: N/A
Study type: Observational

Our hypothesis is that patients with GERD and/or Eosinophilic Esophagitis (EE) have lower esophageal impedance measurements when compared to patients who do not have GERD or EE.

NCT ID: NCT02318862 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Assessment of Esophageal Epithelium Integrity With Mucosal Impedance

Start date: July 2013
Phase: N/A
Study type: Interventional

Gastroesophageal reflux disease (GERD) is a common condition affecting more than 100 million adults in the U.S., and it significantly impacts patients' quality of life while imposing billions of dollars of direct and indirect costs each year upon our healthcare system. Current diagnostic tests for GERD are highly invasive and medically inadequate, and the goal of this project is to develop a novel, minimally invasive Mucosal Impedance technique for more accurate detection of GERD while reducing costs.

NCT ID: NCT02141711 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses

TAK-438_107
Start date: October 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel, multiple-dose schedule.

NCT ID: NCT01940185 Active, not recruiting - Clinical trials for Gastroesophageal Reflux Disease (GERD)

A Post-Approval Study of the LINX® Reflux Management System

Start date: June 2012
Phase: N/A
Study type: Observational

A Post-Approval Study of the LINX® Reflux Management System in a prospective, multicenter, single-arm study, with patients as their own control to monitor the safety and efficacy of the LINX implant procedure and device in a post-approval environment to supplement existing safety and efficacy data.